Price range: $485.00 through $750.00
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog studied for its influence on endogenous growth hormone pulsatility and downstream IGF-1 signaling pathways. In controlled research environments, it is evaluated for metabolic regulation, lipolytic signaling, and body-composition modeling.
As a stabilized GHRH analog, Tesamorelin stimulates the pituitary gland within research models to assess physiologic growth hormone release patterns rather than supplying exogenous hormone directly.
Research Name: Tesamorelin
Alias: TH9507
Category: GHRH analog peptide
Primary Research Focus: Growth hormone pulsatility, IGF-1 signaling, visceral adiposity modeling
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
Tesamorelin is studied for its potential influence on:
Growth Hormone Axis Activity
Endogenous GH pulse amplification
Pituitary signaling dynamics
IGF-1 trend evaluation
Metabolic & Lipolytic Pathways
Visceral adipose tissue modeling
Lipid metabolism analysis
Body-composition trend tracking
Glucose & Endocrine Variables
Insulin sensitivity models
Metabolic hormone interaction frameworks
Muscle & Recovery Signaling
Anabolic pathway observation
Protein synthesis trend analysis
Its mechanism differs from direct growth hormone administration, as it promotes physiologic release patterns through upstream signaling pathways.
Within structured research environments, investigators may observe:
Dose-dependent variables
IGF-1 level fluctuations
Fluid retention trends
Mild joint or soft-tissue sensitivity
Metabolic observations
Glucose variability
Appetite changes
Lipid profile shifts
Less frequent observations
Headache
Injection-site irritation
Mild gastrointestinal discomfort
Monitoring is often focused on endocrine markers due to GH-axis involvement.
Administration Frequency: Commonly daily within study models
Common Study Duration: 8–12 weeks
Titration Strategy: Gradual adjustments to evaluate hormonal response and tolerability
Researchers frequently monitor IGF-1 levels and metabolic markers throughout structured protocols. Caution is typically exercised when combining Tesamorelin with other GH-modulating agents to avoid compounded endocrine signaling.
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
